Next Article in Journal
The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond
Next Article in Special Issue
Telomerase Activity is Downregulated Early During Human Brain Development
Previous Article in Journal
The Roles of NDR Protein Kinases in Hippo Signalling
Article Menu

Export Article

Open AccessReview
Genes 2016, 7(6), 22; doi:10.3390/genes7060022

Telomere and Telomerase Therapeutics in Cancer

Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Gabriele Saretzki
Received: 22 April 2016 / Revised: 18 May 2016 / Accepted: 20 May 2016 / Published: 26 May 2016
(This article belongs to the Special Issue Telomerase Activity in Human Cells)
View Full-Text   |   Download PDF [918 KB, uploaded 26 May 2016]   |  

Abstract

Telomerase is a reverse transcriptase capable of utilizing an integrated RNA component as a template to add protective tandem telomeric single strand DNA repeats, TTAGGG, to the ends of chromosomes. Telomere dysfunction and telomerase reactivation are observed in approximately 90% of human cancers; hence, telomerase activation plays a unique role as a nearly universal step on the path to malignancy. In the past two decades, multiple telomerase targeting therapeutic strategies have been pursued, including direct telomerase inhibition, telomerase interference, hTERT or hTERC promoter driven therapy, telomere-based approaches, and telomerase vaccines. Many of these strategies have entered clinical development, and some have now advanced to phase III clinical trials. In the coming years, one or more of these new telomerase-targeting drugs may be expected to enter the pharmacopeia of standard care. Here, we briefly review the molecular functions of telomerase in cancer and provide an update about the preclinical and clinical development of telomerase targeting therapeutics. View Full-Text
Keywords: telomeres; telomerase; targeted therapy telomeres; telomerase; targeted therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xu, Y.; Goldkorn, A. Telomere and Telomerase Therapeutics in Cancer. Genes 2016, 7, 22.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top